A case of extreme prematurity and delayed diagnosis of pyridoxine-dependent epilepsy

Abdulaziz S Al-Saman1, Tamer M Rizk

  • 1Department of Pediatric Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.

Insights

Pyridoxine-dependent epilepsy, a rare condition, requires lifelong vitamin B6 treatment. Early diagnosis and management are crucial, even in premature infants with difficult-to-treat seizures.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a severe genetic disorder presenting in infancy.
  • It is characterized by refractory seizures unresponsive to standard antiepileptic drugs.
  • Lifelong pyridoxine (vitamin B6) supplementation is the only effective treatment.

Observation:

  • A premature infant born at 25 weeks gestation exhibited abnormal movements and refractory status epilepticus.
  • Seizures were resistant to multiple antiepileptic medications.
  • Intravenous pyridoxine successfully controlled the seizures.

Findings:

  • Elevated urinary α-aminoadipic semialdehyde confirmed PDE.
  • Genetic analysis revealed a homozygous c.1195G>C mutation in the ALDH7A1 gene.
  • The ALDH7A1 gene encodes aldehyde dehydrogenase 7 family member A1.

Implications:

  • This case highlights the importance of considering PDE in infants with unexplained, refractory seizures, irrespective of prematurity.
  • Early diagnosis and pyridoxine treatment can prevent severe neurological consequences.
  • Genetic confirmation of ALDH7A1 mutations solidifies the diagnosis and guides long-term management.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...